8-K: uniQure Secures $175M Hercules Loan for Refinancing, AMT-130

uniQure N.V. amended its loan agreement with Hercules Capital, securing up to $175 million to refinance existing debt and fund general corporate purposes, contingent on key clinical and financing milestones.

Summary

• uniQure N.V. (the Company) and its affiliates entered into Amendment No. 3 to the Third Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. on September 22, 2025.
• The amendment provides for additional term loans in a maximum aggregate amount of $175 million (the 2025 Term Loan).
• On the closing date, uniQure drew down $50 million of the 2025 Term Loan to refinance existing term loans, of which $50 million was outstanding.
• An additional $100 million (Tranche 2) is available subject to achieving the Tranche 2 Milestone, which requires raising more than $150 million prior to March 15, 2027, and FDA approval of a Biologics License Application (BLA) for AMT-130 prior to June 15, 2027.
• A further $25 million (Tranche 3) is available in a single advance, subject to approval by the Hercules investment committee.
• Advances under the 2025 Term Loan bear interest at a rate equal to the greater of 9.45% and the sum of the prime rate and 2.45%.
• The principal balance and all accrued but unpaid interest are due on October 1, 2030.
• Amortization will occur in equal installments commencing in October 2028, or in October 2029 if the Tranche 2 Milestone is met.
• No amortization will occur if the Company meets or exceeds agreed-to revenue targets related to AMT-130 prior to December 31, 2028.
• Prepayment charges apply: 1.50% if paid within the first 30 months, and 0.75% thereafter, with an exception for Change in Control prepayments within 18 months after the 2025 Closing Date.
• The agreement includes various End of Term Charges, including an Initial Back End Fee and a Subsequent Back End Fee, partially accrued prior to the 2025 Closing Date, and a Term Loan End of Term Charge of 2.75% (first 18 months) or 5.50% (thereafter) of the principal amount.

Sentiment

Score: 7

Explanation: The financing provides crucial liquidity and extends the company's runway, which is positive. However, the high cost of debt and the contingent nature of significant tranches tied to challenging clinical and financial milestones introduce considerable execution risk. The terms are generally expected for a clinical-stage biotech, but the success hinges on AMT-130's progress.

Positives

• Secured up to $175 million in new debt financing, providing significant liquidity and extending the company's financial runway.
• The loan refinances existing debt, potentially optimizing the company's debt structure.
• The maturity date for the loan is extended to October 1, 2030, offering a longer period for repayment.
• Amortization can be deferred or waived based on the clinical and commercial success of AMT-130, aligning the loan terms with the company's strategic goals.
• The availability of additional tranches is contingent on achieving significant positive events, such as FDA approval for AMT-130 and a substantial capital raise, indicating potential for future growth and de-risking.

Negatives

• The interest rate is relatively high, at the greater of 9.45% or the sum of the prime rate and 2.45%, increasing the cost of capital.
• Access to the additional $100 million (Tranche 2) is contingent on challenging milestones, including FDA approval for AMT-130 and raising over $150 million, which may not be met.
• Prepayment charges of 1.50% (first 30 months) or 0.75% (thereafter) limit financial flexibility for early repayment, unless a Change in Control occurs within 18 months.
• Various End of Term Charges (Initial Back End Fee, Subsequent Back End Fee, Term Loan End of Term Charge) add to the overall cost of the loan.
• The agreement imposes financial covenants, including minimum Unrestricted Cash requirements and a Performance Covenant based on Net Product Revenue, which could restrict operational flexibility.

Risks

• **Clinical Development Risk**: Failure to achieve FDA approval for the AMT-130 Biologics License Application (BLA) by June 15, 2027, would prevent access to the $100 million Tranche 2.
• **Financing Risk**: Inability to raise more than $150 million prior to March 15, 2027, from equity, convertible debt, or business development deals, would also prevent access to the $100 million Tranche 2.
• **Commercialization Risk**: Failure to meet AMT-130 revenue targets ($50 million by September 30, 2028, or $150 million cumulative by December 31, 2028) could result in earlier amortization commencement and potential breaches of performance covenants.
• **Liquidity Risk**: Failure to maintain minimum Unrestricted Cash levels (65% of outstanding Term Loan Advances, potentially reduced to 50% or 35% with milestones) could lead to an Event of Default.
• **Market Capitalization Risk**: If the company's Market Capitalization falls below $1.2 billion, the waiver for the minimum cash covenant is removed, increasing liquidity pressure.
• **High Cost of Debt**: The high interest rate and various End of Term Charges represent a significant financial burden on the company.
• **Collateral Risk**: The loan is secured by a first-ranking pledge on shares of key subsidiaries and a security interest in US Borrower's personal property, including 'Rights to Payment' from Intellectual Property, which could be at risk in case of default.

Future Outlook

The company's future outlook is significantly tied to the successful development and commercialization of its gene therapy candidate, AMT-130, for Huntington's disease. The loan structure provides crucial capital for advancing this program, with additional funding tranches and amortization deferrals contingent on achieving key regulatory (FDA approval) and financial (capital raise, revenue generation) milestones. The company aims to generate substantial Net Product Revenue from AMT-130 by late 2028, which would further de-risk the loan and support long-term growth.

Management Comments

• Borrower acknowledges that each of Agent and Lender has acted in good faith and has conducted in a commercially reasonable manner its relationships with Borrower in connection with this Amendment and in connection with the Loan Documents.
• Borrower understands and acknowledges that each of Agent and Lender is entering into this Amendment in reliance upon, and in partial consideration for, the above representations and warranties, and agrees that such reliance is reasonable and appropriate.

Industry Context

This financing is a common strategy for clinical-stage biopharmaceutical companies like uniQure, which require substantial capital to fund late-stage clinical trials and prepare for potential commercialization. Gene therapy development is inherently capital-intensive and high-risk. Securing non-dilutive debt financing, even with performance-based tranches, can be an attractive alternative to equity raises, especially if the company has strong conviction in its lead asset, AMT-130. The milestones tied to FDA approval and revenue generation reflect the broader industry trend of lenders seeking to de-risk investments by linking funding to key development and commercialization achievements. The relatively high interest rate is typical for venture debt in the biotech sector, reflecting the elevated risk profile compared to more mature industries.

Comparison to Industry Standards

• The loan amount of up to $175 million is substantial for a clinical-stage biotech company, indicating a notable level of confidence from Hercules Capital in uniQure's potential, particularly with its lead asset, AMT-130.
• The interest rate of 9.45% or Prime + 2.45% is within the typical range for venture debt provided to biotech firms, which often face higher borrowing costs due to the inherent risks of drug development compared to established, revenue-generating companies.
• The inclusion of clinical (FDA approval for AMT-130) and financial (capital raise, revenue targets) milestones for additional tranches and amortization deferral is a standard and widely adopted structure in venture debt for the biotech industry. This approach aligns the lender's interests with the borrower's success in de-risking its pipeline, similar to deals seen with companies like Sarepta Therapeutics or Bluebird Bio in their earlier stages of gene therapy development.
• The minimum cash covenant (65% of outstanding loan, reducing with milestones) is a common liquidity requirement, though specific percentages can vary. The waiver based on a market capitalization of $1.2 billion provides a flexible mechanism for a publicly traded company, comparable to covenants in debt facilities for peers such as Sangamo Therapeutics or Voyager Therapeutics.
• The collateral package, including pledges on subsidiary shares and 'Rights to Payment' from Intellectual Property, is a standard practice for venture debt in the life sciences sector, where intellectual property is often the most valuable asset, mirroring security arrangements in similar financing for companies like Editas Medicine or CRISPR Therapeutics.

Stakeholder Impact

• **Shareholders**: Potential for dilution if the $150 million financing milestone is met via equity issuance. The loan provides runway, which could be positive if AMT-130 succeeds, but the high cost of debt could impact future profitability. The stock price could be influenced by the market's perception of the company's ability to meet the milestones.
• **Employees**: Continued operations and funding for research and development, particularly for AMT-130, support job security and ongoing work.
• **Creditors (Hercules Capital)**: Secured position with pledges on shares of key subsidiaries and IP-related 'Rights to Payment,' providing a degree of protection for their investment.
• **Patients (Huntington's Disease)**: Continued funding for AMT-130 development offers hope for a new treatment option.

Next Steps

• Achieve the Tranche 2 Milestone by raising over $150 million prior to March 15, 2027.
• Obtain FDA approval for the Biologics License Application (BLA) for AMT-130 prior to June 15, 2027, to unlock the $100 million Tranche 2.
• Seek approval from the Hercules investment committee for the $25 million Tranche 3 Advance.
• Work towards achieving Commercial Milestone 1 ($50 million Net Product Revenue by September 30, 2028) or Commercial Milestone 2 ($150 million cumulative Net Product Revenue by December 31, 2028) to potentially waive amortization.
• Maintain minimum Unrestricted Cash levels and comply with the Performance Covenant related to Net Product Revenue.

Key Dates

Recommendation

The financing provides essential liquidity and extends the company's operational runway, which is a positive development for a clinical-stage biotech. However, a significant portion of the loan is contingent on achieving challenging clinical (FDA approval for AMT-130) and financial (raising $150M+) milestones. While the potential upside from AMT-130's success is high, the execution risk remains substantial, and the cost of debt is considerable. Investors should hold, awaiting clearer data on AMT-130's regulatory path and the company's ability to meet the financing and commercialization milestones before making further investment decisions.

Keywords

uniQure, QURE, Hercules Capital, Loan Agreement, Debt Financing, Gene Therapy, AMT-130, Huntington's Disease, BLA Approval, FDA Approval, Financial Milestones, Clinical Milestones, Refinancing, Working Capital, Biopharmaceutical, Biotech